Jefferies Financial Group Inc. Takes $371,000 Position in Pulmonx Corporation $LUNG

Jefferies Financial Group Inc. purchased a new position in shares of Pulmonx Corporation (NASDAQ:LUNG) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 285,110 shares of the company’s stock, valued at approximately $371,000. Jefferies Financial Group Inc. owned 0.66% of Pulmonx at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC purchased a new position in Pulmonx in the 4th quarter valued at about $27,000. Opal Capital LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth about $29,000. Lazard Asset Management LLC acquired a new position in shares of Pulmonx in the fourth quarter worth about $31,000. Jain Global LLC acquired a new position in shares of Pulmonx in the third quarter worth about $30,000. Finally, R Squared Ltd purchased a new position in Pulmonx in the first quarter valued at about $26,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Wall Street Analysts Forecast Growth

LUNG has been the topic of several analyst reports. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.67.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $2.38 on Tuesday. The company has a market cap of $102.22 million, a PE ratio of -2.05 and a beta of 0.28. Pulmonx Corporation has a fifty-two week low of $1.13 and a fifty-two week high of $2.89. The firm has a 50-day simple moving average of $1.75 and a 200 day simple moving average of $1.54. The company has a quick ratio of 3.52, a current ratio of 4.32 and a debt-to-equity ratio of 0.95.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. The firm had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. On average, sell-side analysts anticipate that Pulmonx Corporation will post -1.05 EPS for the current year.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.